Helsinn and Fosun Pharma sign exclusive license and distribution agreements for Aloxi®, Akynzeo® oral, NEPA IV and anamorelin in Mainland China, Hong Kong SAR and Macau SAR

NEXT STORY
Antimicrobial Susceptibility Testing Market Predicted to Reach $4.73 Billion by 2030, Exclusive Report by Allied Market Research
PREV STORY
OSE Immunotherapeutics to Host Today a Virtual “Immuno-Oncology R&D Day”
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Endoscopy Equipment Market Rising at Steady 4.0% CAGR during 2017 to 2022; Owing to Their Increasing Usage in Treating Gastroenterology – TMR

Endoscopy Equipment Market (Product Type - Endoscopes, Operative Devices, Visualization Systems; Application - Gastroenterology, ...

author_avatar
NASDAQ Market News

US Defense Reports Broad Travelan® Reactivity to 180 Pathogenic Bacteria Including Camylobacter and Shigella

Key Highlights: The research program was performed by the U.S. Department of Defense (DoD) ...

author_avatar
NASDAQ Market News

EDAP’s Ablatherm® Robotic HIFU Treats First Patient at Henry Ford Hospital in Detroit

LYON, France, Aug. 22, 2016 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader ...

author_avatar
NASDAQ Market News